This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Siddall et al. conclude with a bullish statement on the effectiveness of pregabalin. The article, acknowledging that all authors worked for or were supported by Pfizer, obfuscates several problems with pregabalin.1
The first problem is study design; all patients were permitted to remain on existing pain therapies except the individuals taking gabapentin, who were required to discontinue treatment at least a week before the study protocol began. This intentionally produced a gabapentin withdrawal state in 34 clients.1 The study may have been biased because those receiving pregabalin were receiving replacement therapy as a byproduct of pre-study drug manipulation; randomization was completed after gabapentin was withdrawn; and the authors did not report which subjects in gabapentin withdrawal were randomized to which treatment group.
The second problem concerns safety. The pregabalin group manifested significantly more adverse side effects, including more serious ones. Twenty-one percent more of the pregabalin-treated patients reported treatment-emergent adverse events compared to placebo. The group discontinuing treatment due to pregabalin was 62% higher than those discontinuing treatment due to placebo.
In addition, side effects included somnolence, dizziness, euphoria (3 with pregabalin vs 0 with placebo), and edema. Adverse …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.